Fujirebio Inc.

14 articles about Fujirebio Inc.

• Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics - March 12, 2024

  3/12/2024

  Beckman Coulter Diagnostics today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

• Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

  3/12/2024

  Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic manufacturing, announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

• Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay

  12/14/2023

  Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies.

• Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration

  11/30/2023

  Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.

• Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics

  7/17/2023

  Beckman Coulter Diagnostics and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

• Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only

  3/31/2023

  H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems.

• Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests

  3/28/2023

  H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems.

• Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only

  3/1/2022

  H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G pTau 181 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.

• Fujirebio Europe Receives Translational Research Funding From Alzheimer’s Drug Discovery Foundation for Development of a Fully Automated Plasma pTau181 Testing Solution

  10/28/2021

  H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE® G immunoassay platform.

• Fujirebio Europe and CENTOGENE Enter Partnership to Provide Rapid and High-Quality Preventive SARS-CoV-2 Antigen Testing

  11/9/2020

  Centogene N.V. and Fujirebio Europe announced to have entered a partnership to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing with further deployment in German airports.

• Fujirebio Enters into Agreement with Janssen Pharmaceuticals to Develop and Commercialize AMYLOID β 42/40 RATIO Assay

  4/26/2018

  The Lumipulse® series is intended to help identify patients who may benefit from treatment with Janssen’s new investigational oral BACE inhibitor, atabecestat.

• IRIS International, Inc. and Fujirebio Inc. Sign Joint Development Agreement for IRIS's 3GEMS(TM) Hematology Analyzer Product Line in Japan

  4/4/2011

• Sanko Junyaku Co., Ltd., Eisai Inc. And Fujirebio Inc. Sign Joint Research Agreement For Development Of New KL-6 Test Kit

  10/19/2006

• Fujirebio, Stem Cell Sciences To Co-develop Serum-free Mediums For Stem Cell Culture

  4/26/2004